SCHEMBL4237017

SCHEMBL4237017

O=C(NCc1ccccc1-c1ccccc1C(=O)O)Oc1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 8/20 0.67
HSD17B10 Q99714 1/20 0.49
RAB9A P51151 2/20 0.47
HTT P42858 3/20 0.46
ALDH1A1 P00352 1/20 0.46
NPC1 O15118 1/20 0.46
MAPK1 P28482 1/20 0.46
FOLH1 Q04609 1/20 0.43
KCNK3 O14649 1/20 0.43
KCNA3 P22001 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4244489 0.88 KCNA5 (0.57) KCNA5RAB9AALDH1A1NPC1MAPK1
SCHEMBL4242291 0.85 KCNA5 (0.64) KCNA5RAB9AHTTMAPK1FOLH1
SCHEMBL2210699 0.81 KCNA5 (1.00) KCNA5KCNK3KCNA3
SCHEMBL498661 0.81 KCNA5 (0.67) KCNA5RAB9AHTTMAPK1KCNK3
SCHEMBL2207411 0.81 KCNA5 (0.68) KCNA5HTTALDH1A1KCNK3KCNA3
SCHEMBL12434044 0.79 KCNA5 (0.74) KCNA5RAB9AALDH1A1KCNK3KCNA3
SCHEMBL4241477 0.78 KCNA5 (0.66) KCNA5RAB9AHTTALDH1A1MAPK1
SCHEMBL4236628 0.78 KCNA5 (0.53) KCNA5RAB9AHTTALDH1A1NPC1
SCHEMBL4239368 0.78 PTPN11 (0.51) KCNA5RAB9AALDH1A1NPC1MAPK1
SCHEMBL13789541 0.77 KCNA5 (0.62) KCNA5RAB9AALDH1A1KCNK3KCNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-07-30 US disclosed
US-7514582-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-07 US disclosed
US-20040102513-A1 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2004-05-27 US disclosed
US-6686395-B2 THERAPY OF A CARDIAC ARRYTHMIA WHICH CAN BE ELIMINATED BY ACTION POTENTIAL PROLONGATION; POTASSIUM CHANNEL MODULATOR AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-02-03 US disclosed
US-20030171351-A1 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2003-09-11 US disclosed
US-6531495-B1 Potassium channel AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171351-A1 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them MLLT3, RYR2, KCNH1 KCNA5 104/4885HSD17B10 3045/4885RAB9A 1604/4885
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them MLLT3, RYR2, CACNA1E KCNA5 90/4885HSD17B10 3061/4885RAB9A 1634/4885
US-20040102513-A1 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them MLLT3, RYR2, CACNA1E KCNA5 97/4885HSD17B10 3065/4885RAB9A 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.